ALT
Altimmune, Inc.
$3.23
-0.05
(-1.52%)
Mkt Cap
628.15M
Volume
2,549,889
52W Range
2.56-6.44
Sector
Healthcare
Beta
0.17
EPS (TTM)
-0.78 USD
P/E Ratio
-3.61
Revenue (TTM)
31,000 USD
Rev Growth (5Y)
-65.3%
EPS Growth (5Y)
N/A
Company Description
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41,000 | 20,000 | 426,000 | (68,000) | 4.41M | 8.19M | 5.80M | 10.33M | 41,503 | 5.23M | 10.64M | 10.19M |
| Net Income | (88.09M) | (95.06M) | (88.45M) | (84.71M) | (97.09M) | (49.04M) | (20.52M) | (39.17M) | (46.43M) | 193.85M | (3.44M) | (9.96M) |
| EPS | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 |
| Free Cash Flow | (67.55M) | (79.85M) | (75.86M) | (62.71M) | (90.55M) | (34.65M) | (9.60M) | (10.40M) | (20.38M) | 201.48M | (3.30M) | (8.57M) |
| FCF / Share | -0.77 | -1.12 | -1.42 | -1.34 | -2.19 | -1.35 | -0.73 | -3.71 | -47.75 | 874.54 | -15.48 | -44.67 |
| Operating CF | (67.53M) | (79.85M) | (75.81M) | (62.59M) | (78.24M) | (34.31M) | (9.60M) | (9.39M) | (20.21M) | 201.51M | (3.22M) | (8.47M) |
| Total Assets | 279.93M | 139.31M | 210.64M | 206.93M | 218.87M | 245.12M | 54.06M | 54.75M | 63.03M | 224.74M | 19.86M | 21.98M |
| Total Debt | 35.69M | 1.68M | 671,000 | 1.12M | 1.53M | 1.82M | 1.74M | 572,770 | 49,702 | 984,580 | 1.08M | 746,146 |
| Cash & Equiv | 43.76M | 36.93M | 135.12M | 111.10M | 190.30M | 115.92M | 8.96M | 33.72M | 8.77M | 153.99M | 15.57M | 18.64M |
| Book Value | 224.89M | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M | 45.52M | 48.31M | 48.68M | 19.46M | 16.65M | 18.27M |
| Return on Equity | -0.39 | -0.77 | -0.46 | -0.46 | -0.49 | -0.22 | -0.45 | -0.81 | -0.95 | 9.96 | -0.21 | -0.54 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 26,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 37,000 | 362,000 |
| Net Income | (22.82M) | (22.56M) | (27.36M) | (19.01M) | (22.15M) | (19.57M) | (23.18M) | (22.84M) | (24.64M) | (24.39M) | (31.64M) | (20.67M) |
| EPS | -0.12 | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 | -0.39 |
| Free Cash Flow | (24.25M) | (20.96M) | (19.45M) | (11.90M) | (19.36M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) |
| FCF / Share | -0.13 | -0.17 | -0.19 | -0.13 | -0.24 | -0.22 | -0.26 | -0.38 | -0.26 | -0.23 | -0.28 | -0.38 |
| Operating CF | (24.22M) | (20.94M) | (19.45M) | (11.90M) | (19.35M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) |
| Total Assets | 527.21M | 335.63M | 279.93M | 218.45M | 190.35M | 157.26M | 139.31M | 147.86M | 173.35M | 188.36M | 210.64M | 166.57M |
| Total Debt | 35.75M | 35.85M | 35.69M | 15.90M | 15.85M | 1.59M | 1.68M | 1.77M | 1.86M | 552,000 | 671,000 | 788,000 |
| Cash & Equiv | 63.05M | 97.60M | 43.76M | 61.24M | 183.10M | 49.10M | 36.93M | 31.47M | 57.13M | 78.98M | 135.12M | 86.86M |
| Book Value | 474.21M | 283.99M | 224.89M | 185.60M | 161.37M | 142.16M | 123.51M | 133.38M | 152.53M | 172.94M | 194.10M | 150.40M |
| Return on Equity | -0.05 | -0.08 | -0.12 | -0.10 | -0.14 | -0.14 | -0.19 | -0.17 | -0.16 | -0.14 | -0.16 | -0.14 |
ALT News
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Analysts
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune Q2 Earnings Call Highlights
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026